Detalhe da pesquisa
1.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Haematologica
; 106(6): 1599-1607, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499241
2.
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Biol Blood Marrow Transplant
; 26(4): 798-804, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31756536
3.
Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.
Biol Blood Marrow Transplant
; 25(2): 335-342, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30243581
4.
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Haematologica
; 104(2): 380-391, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262560
5.
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Biol Blood Marrow Transplant
; 24(5): 930-936, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29339268
6.
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.
Biol Blood Marrow Transplant
; 23(4): 618-624, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28087456
7.
Cytomegalovirus sinusitis complicated by orbital apex syndrome in an immunocompromised host.
Transpl Infect Dis
; 18(6): 957-959, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27677910
8.
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 21(12): 2136-2140, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26211987
9.
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.
Am J Clin Oncol
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38483213
10.
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
Biol Blood Marrow Transplant
; 19(2): 260-5, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23073267
11.
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.
Br J Haematol
; 160(2): 199-206, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23151215
12.
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Lancet Haematol
; 10(1): e14-e23, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403579
13.
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Biol Blood Marrow Transplant
; 18(3): 486-92, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22198542
14.
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.
Br J Haematol
; 178(5): 816-819, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27292583
15.
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Lancet Oncol
; 12(13): 1195-203, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21962393
16.
Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.
Transplant Cell Ther
; 28(7): 367.e1-367.e9, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534000
17.
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.
Blood
; 113(14): 3383-91, 2009 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-19015394
18.
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
JAMA
; 306(17): 1874-83, 2011 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22045765
19.
Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Transplant Cell Ther
; 27(12): 999.e1-999.e10, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543768
20.
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma.
Blood Adv
; 5(23): 5300-5311, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638132